During acute infection, virus-specific effector CD8+ T cells heterogeneously express P2RX7, an ATP-gated purinergic receptor that senses extracellular ATP (eATP); P2RX7-high early effectors preferentially adopt a pro-memory transcriptional program and generate long-lived central-memory and tissue-resident-memory cells. The source study (Vardam-Kaur et al., J Immunol 2022) established this correlation and parts of the causal circuit — including repression of the terminal-effector transcription factor Zeb2, partly via P2RX7-dependent TGF-β signaling — but left open the mechanisms that set up, maintain, and transmit this imprint. This problem asks for the mechanistic dissection of P2RX7-dependent memory-fate imprinting: whether TCF-1 reinforces P2RX7 expression in a positive-feedback loop, whether P2RX7 asymmetry originates at the first division and is coupled to asymmetric inheritance of known fate determinants, whether memory arising from P2RX7-low effectors reflects early differentiation or dedifferentiation, whether epigenetic modifications at the P2rx7 locus explain why P2RX7-low memory precursors can re-upregulate P2RX7 whereas the circulating progeny of P2RX7-low early effectors cannot, whether early P2RX7 signaling selectively generates a longer-lived tissue-resident-memory subset, and which molecular intermediates besides TGF-β connect P2RX7 to Zeb2 repression. All six sub-questions were posed as unresolved by the source paper and, as of August 2026, no published work has answered them.

Background

CD8+ T cells that clear acute viral infection differentiate into short-lived terminal effector (TE) cells and long-lived memory cells, including central memory (Tcm) cells that recirculate through lymphoid organs and tissue-resident memory (Trm) cells that lodge in barrier tissues. Fate allocation begins within the first days of activation: among 'early effector' CD8+ T cells, a memory-precursor-like transcriptional program (expression of genes such as Tcf7, Il7r, Sell, Bcl2) predicts memory potential, while a terminal-effector program (e.g., Zeb2, Gzmb, KlrG1) predicts short-lived cytotoxic output. TCF-1 (T cell factor 1, encoded by Tcf7) is a pro-memory transcription factor required for memory-precursor and stem-like CD8+ T cell states; T-bet and ZEB2 are transcription factors that promote terminal-effector differentiation, and ZEB2 is counter-regulated by the microRNA-200 family and by TGF-β signaling; mTORC1 (mechanistic target of rapamycin complex 1) is a growth-and-metabolism regulator whose asymmetric activity during division biases effector versus memory fates. Asymmetric (unequal) partitioning of proteins and signaling components at the first division of a naive CD8+ T cell is one proposed mechanism by which daughter cells diverge toward effector versus memory fates; an alternative, not mutually exclusive view holds that memory cells can arise by dedifferentiation of committed effector cells during the contraction phase.

P2RX7 is a trimeric ATP-gated ion channel (a purinergic receptor) expressed on T cells that senses extracellular ATP released at sites of inflammation and tissue damage. Prior work showed that P2RX7 directs the metabolic fitness of long-lived memory CD8+ T cells (Borges da Silva et al., Nature 2018) and that P2RX7-mediated eATP sensing promotes Trm cell generation by enhancing sensitivity to TGF-β in nonlymphoid tissues (Borges da Silva et al., Immunity 2020). ATP for P2RX7 engagement is in part exported by the channel Pannexin 1, whose T-cell-specific deletion impairs effector and memory CD8+ T cell responses (Vardam-Kaur et al., iScience 2024). The source study for this problem (Vardam-Kaur et al., J Immunol 2022) showed that P2RX7 expression among early effector CD8+ T cells (days ~4–5 after lymphocytic choriomeningitis virus infection) is asymmetric and bifurcates fates: P2RX7-high cells are enriched for memory and tissue-residency gene sets, preferentially form memory populations, and repress Zeb2 indirectly — at least partly through induction of TGF-β signaling, since overexpression of Tgfbr2 (encoding the type II TGF-β receptor) largely restored negative regulation of Zeb2 in P2RX7-deficient effectors. Zeb2 ablation redirected P2RX7-deficient cells toward memory differentiation, but incompletely (with the caveat that average Zeb2 knockout efficiency was 82.9%, so residual Zeb2 could account for part of the incomplete rescue), indicating additional P2RX7-controlled pathways. The authors also found that P2RX7-high-derived Trm cells tended to survive longer, and that histone-deacetylase (HDAC)-related gene sets were enriched in P2RX7-low early effectors. A report on chronic viral infection (Jadhav et al., PNAS 2019) suggests that TCF-1 can bind the P2rx7 enhancer locus in CD8+ T cells, while P2RX7 is upregulated before TCF-1 re-expression, leaving the causal ordering unclear.

Problem Statement

Define the mechanisms by which heterogeneous P2RX7 expression and extracellular-ATP sensing in early effector CD8+ T cells is established, maintained, and translated into pro-memory differentiation and durable memory, by answering the following interlinked questions left open by Vardam-Kaur et al. (J Immunol 2022):

All six sub-questions below are jointly required for completion: a solution must address every one of them, and resolving only a subset does not resolve the task. Each sub-question is independently refutable, and a refutation of any one is reported against that sub-question while the others remain open.

  1. TCF-1/P2RX7 hierarchy: P2RX7 is upregulated before TCF-1 re-expression, yet a report in chronic infection suggests that TCF-1 can bind the P2rx7 enhancer; determine whether (and how) TCF-1 re-expression reinforces high P2RX7 expression in memory-bound early effectors, including whether a P2RX7-to-TCF-1-to-P2RX7 positive-feedback loop operates.

  2. Origin and timing of P2RX7 asymmetry: determine whether unequal P2RX7 distribution arises at (or before) the first division of activated naive CD8+ T cells — earlier than the day-4/5 peak examined in the source study — and whether it is mechanistically linked to asymmetric inheritance of TCF-1, T-bet, or mTORC1.

  3. Origin of P2RX7-low-derived memory: P2RX7-low early effectors form memory cells less efficiently than P2RX7-high cells; determine whether this memory arises from early differentiation events in a memory-leaning subpopulation or from dedifferentiation of terminal-effector-leaning cells during the contraction phase.

  4. Epigenetic control of P2rx7 expression dynamics: the circulating progeny of P2RX7-low early effectors never re-upregulate P2RX7, even the few that develop into Tcm cells, whereas P2RX7-low memory precursors can; determine whether epigenetic modifications at the P2rx7 locus (candidate mechanisms include the HDAC-related pathways enriched in P2RX7-low cells) establish or maintain this cell-type-specific difference in re-expression, and what relieves or rewrites such modifications. The source study treated Trm cells as a separate case — even the few P2RX7-low early effectors that differentiate into Trm cells express high levels of P2RX7 — and proposed that other signaling pathways and transcriptional controllers acting at the P2rx7 locus after nonlymphoid-tissue entry (for example retinoic acid signaling) may account for Trm re-expression rather than the epigenetic control at issue here.

  5. Trm durability: determine whether P2RX7 signaling during the early effector phase selectively generates a longer-lived Trm subset compared with Trm cells derived from non-imprinted (P2RX7-low) effectors, as the survival skew observed in the source study suggests.

  6. Intermediates from P2RX7 to Zeb2 repression: beyond the already-demonstrated TGF-β arm, identify the molecular intermediates (candidates include TCF-1 and the miR-200 microRNA family) through which P2RX7 upregulation represses Zeb2 and promotes the pro-memory program, including any P2RX7-controlled pathways (e.g., metabolism regulated by AMP-activated protein kinase [AMPK], a cellular energy-sensing kinase) that account for the incomplete rescue upon Zeb2 ablation, controlling for the incomplete knockout efficiency reported in the source study.

References

  1. Vardam-Kaur T, van Dijk S, Peng C, Wanhainen KM, Jameson SC, Borges da Silva H. The Extracellular ATP Receptor P2RX7 Imprints a Promemory Transcriptional Signature in Effector CD8+ T Cells. The Journal of Immunology 208(7):1686-1699 (2022). doi:10.4049/jimmunol.2100555, https://doi.org/10.4049/jimmunol.2100555, PMID 35264459, PMCID PMC8976739.
  2. Borges da Silva H, Beura LK, Wang H, Hanse EA, Gore R, Scott MC, Walsh DA, Block KE, Fonseca R, Yan Y, Hippen KL, Blazar BR, Masopust D, Kelekar A, Vulchanova L, Hogquist KA, Jameson SC. The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8+ T cells. Nature 559(7713):264-268 (2018). doi:10.1038/s41586-018-0282-0, https://doi.org/10.1038/s41586-018-0282-0
  3. Borges da Silva H, Peng C, Wang H, Wanhainen KM, Ma C, Lopez S, Khoruts A, Zhang N, Jameson SC. Sensing of ATP via the Purinergic Receptor P2RX7 Promotes CD8+ Trm Cell Generation by Enhancing Their Sensitivity to the Cytokine TGF-β. Immunity 53(1):158-171.e6 (2020). doi:10.1016/j.immuni.2020.06.010, https://doi.org/10.1016/j.immuni.2020.06.010
  4. Jadhav RR, Im SJ, Hu B, Hashimoto M, Li P, Lin JX, Leonard WJ, Greenleaf WJ, Ahmed R, Goronzy JJ. Epigenetic signature of PD-1+ TCF1+ CD8 T cells that act as resource cells during chronic viral infection and respond to PD-1 blockade. Proceedings of the National Academy of Sciences USA 116(28):14113-14118 (2019). doi:10.1073/pnas.1903520116, https://doi.org/10.1073/pnas.1903520116
  5. Guan T, Dominguez CX, Amezquita RA, Laidlaw BJ, Cheng J, Henao-Mejia J, Williams A, Flavell RA, Lu J, Kaech SM. ZEB1, ZEB2, and the miR-200 family form a counterregulatory network to regulate CD8+ T cell fates. The Journal of Experimental Medicine 215(4):1153-1168 (2018). doi:10.1084/jem.20171352, https://doi.org/10.1084/jem.20171352
  6. Kok L, Dijkgraaf FE, Urbanus J, Bresser K, Vredevoogd DW, Cardoso RF, Perié L, Beltman JB, Schumacher TN. A committed tissue-resident memory T cell precursor within the circulating CD8+ effector T cell pool. The Journal of Experimental Medicine 217(10):e20191711 (2020). doi:10.1084/jem.20191711, https://doi.org/10.1084/jem.20191711
  7. Wanhainen KM, Peng C, Zhou MH, Macedo BG, O'Flanagan S, Yang T, Kelekar A, Burbach BJ, Borges da Silva H, Jameson SC. P2RX7 Enhances Tumor Control by CD8+ T Cells in Adoptive Cell Therapy. Cancer Immunology Research 10(7):871-884 (2022). doi:10.1158/2326-6066.cir-21-0691, https://doi.org/10.1158/2326-6066.cir-21-0691
  8. Vardam-Kaur T, Banuelos A, Gabaldon-Parish M, Macedo BG, Salgado CL, Wanhainen KM, Zhou MH, van Dijk S, Santiago-Carvalho I, Beniwal AS, Leff CL, Peng C, Tran NL, Jameson SC, Borges da Silva H. The ATP-exporting channel Pannexin 1 promotes CD8+ T cell effector and memory responses. iScience 27(7):110290 (2024). doi:10.1016/j.isci.2024.110290, https://doi.org/10.1016/j.isci.2024.110290
  9. Santiago-Carvalho I, Banuelos A, Borges da Silva H. Tissue- and temporal-specific roles of extracellular ATP on T cell metabolism and function. Immunometabolism 5(2):e00025 (2023). doi:10.1097/in9.0000000000000025, https://doi.org/10.1097/in9.0000000000000025